Thermo Fisher Scientific Bombesin Receptor 3 Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

Immunohistochemistry (Paraffin) (IHC (P))

Assay-dependent

-

Miscellaneous PubMed (Misc)

-

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human

Published species

Not Applicable

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Synthetic peptide corresponding to residues E(381) I S V T S F T G C S V K Q A E D R F(399) of human BRS3 protein. if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:Bombesin Receptor 3,uniProtId:P32247-1,ncbiNodeId:9606,antigenRange:382-399,antigenLength:399,antigenImageFileName:PA3-302_Bombesin_Receptor_3_P32247-1_Rabbit.svg,antigenImageFileNamePDP:PA3-302_Bombesin_Receptor_3_P32247-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

Conc. Not Determined

Storage buffer

whole serum

Contains

0.05% sodium azide

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Wet ice

RRID

AB_2093771

Product Specific Information

PA3-302 detects BRS3 from human samples.

PA3-302 has been successfully used in Western blot and immunohistochemistry (paraffin) procedures. By Western blot, this antibody detects a ~50-70 kDa protein representing BRS3.

The PA3-302 immunogen is a synthetic peptide corresponding to residues E(381) I S V T S F T G C S V K Q A E D R F(399) of human BRS3 protein.

Target Information

BRS3 expression has been reported in lung (normal and cancer), nasal mucosa, placenta, and uterus. ESTs have been isolated from normal brain and kidney cancer libraries. G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This turn-off activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.